Shares in UK pharma major GSK (LSE: GSK) closed 3% lower on Friday.
This followed the latest update on the legal situation regarding Zantac (ranitidine), the heartburn drug that was initially marketed by GSK.
In recent years, claims that Zantac causes cancer have weighed heavily on GSK and other companies, including Sanofi (Euronext: SAN) and Pfizer (NYSE: PFE), that have sold the drug at various times.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze